Rize Oncology Inc. (RZONF)
OTCMKTS · Delayed Price · Currency is USD
0.1600
+0.1596 (39,900.00%)
At close: May 23, 2025
Rize Oncology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.06 | 0.35 | 1.16 | 1.36 | 1.8 | 0.18 |
Cash & Short-Term Investments | 0.06 | 0.35 | 1.16 | 1.36 | 1.8 | 0.18 |
Cash Growth | -86.01% | -70.19% | -14.78% | -24.06% | 898.49% | 296.21% |
Other Receivables | 0.11 | 0.15 | - | - | - | - |
Receivables | 0.11 | 0.15 | - | - | - | - |
Prepaid Expenses | 0.15 | 0.07 | 0.03 | 0.05 | 0.15 | - |
Other Current Assets | - | - | - | - | - | 0.19 |
Total Current Assets | 0.33 | 0.57 | 1.19 | 1.41 | 1.94 | 0.37 |
Total Assets | 0.33 | 0.57 | 1.19 | 1.41 | 1.94 | 0.37 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.3 | 0.12 | 0.08 | 0.03 | 0.06 | 0.21 |
Other Current Liabilities | - | 0.01 | 0 | 0.01 | 0.02 | - |
Total Current Liabilities | 0.3 | 0.13 | 0.08 | 0.04 | 0.09 | 0.21 |
Total Liabilities | 0.3 | 0.13 | 0.08 | 0.04 | 0.09 | 0.21 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4.93 | 4.89 | 4.2 | 4.2 | 4.18 | 1.25 |
Additional Paid-In Capital | 1.87 | 1.86 | 1.66 | 1.63 | 1.48 | 0.79 |
Retained Earnings | -6.53 | -6.09 | -4.83 | -4.28 | -3.59 | -1.88 |
Comprehensive Income & Other | -0.25 | -0.22 | 0.09 | -0.17 | -0.2 | - |
Shareholders' Equity | 0.02 | 0.45 | 1.11 | 1.37 | 1.86 | 0.16 |
Total Liabilities & Equity | 0.33 | 0.57 | 1.19 | 1.41 | 1.94 | 0.37 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 0.06 | 0.35 | 1.16 | 1.36 | 1.8 | 0.18 |
Net Cash Growth | -86.01% | -70.19% | -14.78% | -24.06% | 898.49% | - |
Net Cash Per Share | 0.00 | 0.00 | 0.03 | 0.03 | 0.04 | 0.01 |
Filing Date Shares Outstanding | 82.48 | 80.74 | 75.74 | 38.74 | 48.38 | 47.85 |
Total Common Shares Outstanding | 82.48 | 80.74 | 38.74 | 38.74 | 48.38 | 38.51 |
Working Capital | 0.02 | 0.45 | 1.11 | 1.37 | 1.86 | 0.16 |
Book Value Per Share | 0.00 | 0.01 | 0.03 | 0.04 | 0.04 | 0.00 |
Tangible Book Value | 0.02 | 0.45 | 1.11 | 1.37 | 1.86 | 0.16 |
Tangible Book Value Per Share | 0.00 | 0.01 | 0.03 | 0.04 | 0.04 | 0.00 |